311 related articles for article (PubMed ID: 17875682)
21. DC-expressed MHC class I single-chain trimer-based vaccines prime cytotoxic T lymphocytes against exogenous but not endogenous antigens.
Ordaz ML; Larmonier N; Lybarger L
Cell Immunol; 2010; 262(2):141-9. PubMed ID: 20199770
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cell-based vaccines in breast and gynaecologic cancer.
Hernando JJ; Park TW; Kuhn WC
Anticancer Res; 2003; 23(5b):4293-303. PubMed ID: 14666641
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.
Melief CJ; Kast WM
Semin Cancer Biol; 1991 Oct; 2(5):347-54. PubMed ID: 1773050
[TBL] [Abstract][Full Text] [Related]
24. [Immunotherapy against tumor with dendritic cell sensitized by necrotic tumor tissue after microwave coagulation therapy].
Yao LC; Yang RJ
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(36):2552-6. PubMed ID: 18067832
[TBL] [Abstract][Full Text] [Related]
25. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
27. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
28. Native anti-tumor responses elicited by immunization with a low dose of unmodified live tumor cells.
Wu S; Wang SQ; Zhang J; Tan XY; Liu JN
Int J Oncol; 2006 Mar; 28(3):731-6. PubMed ID: 16465379
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma.
O-Sullivan I; Kim TS; Chopra A; Cohen EP
Anticancer Res; 2006; 26(2A):873-84. PubMed ID: 16619482
[TBL] [Abstract][Full Text] [Related]
30. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
31. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
32. Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression.
Fong CL; Mok CL; Hui KM
Gene Ther; 2006 Feb; 13(3):245-56. PubMed ID: 16163376
[TBL] [Abstract][Full Text] [Related]
33. [Antitumor immunity and cellular cancer therapies].
Catros-Quemener V; Bouet F; Genetet N
Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
[TBL] [Abstract][Full Text] [Related]
34. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity.
Vingert B; Adotevi O; Patin D; Jung S; Shrikant P; Freyburger L; Eppolito C; Sapoznikov A; Amessou M; Quintin-Colonna F; Fridman WH; Johannes L; Tartour E
Eur J Immunol; 2006 May; 36(5):1124-35. PubMed ID: 16568496
[TBL] [Abstract][Full Text] [Related]
35. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
Fujii S
Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
[TBL] [Abstract][Full Text] [Related]
36. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
Sas S; Chan T; Sami A; El-Gayed A; Xiang J
Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
[TBL] [Abstract][Full Text] [Related]
37. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
38. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity.
den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Frielink C; Toonen LW; Boerman OC; Figdor CG; Ruers TJ; Adema GJ
Br J Cancer; 2006 Oct; 95(7):896-905. PubMed ID: 16953240
[TBL] [Abstract][Full Text] [Related]
39. Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens.
Dao T; Gomez-Nunez M; Antczak C; Kappel B; Jaggi JS; Korontsvit T; Zakhaleva V; Scheinberg DA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8763-72. PubMed ID: 16361564
[TBL] [Abstract][Full Text] [Related]
40. Dendritic cells from bench to bedside and back.
Adema GJ
Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
